From: Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
AATD genotype | AAT polymers (µg/mL) | AAT polymers (%) | AAT (mg/dL) |
---|---|---|---|
Patients (n = 70) | |||
Pi*ZZ treated (n = 11) | 42.9 (16) | 9.2 (9.6) | 73.5 (46.9) |
Pi*FZ (n = 1) | 42.1 (–) | 6.2 (–) | 67.7 (–) |
Pi*ZZ untreated (n = 21) | 34.5 (16.2) | 14.7 (4.8) | 23.1 (5.9) |
Pi*MmaltonZ (n = 1) | 22.8 (–) | 10.2 (–) | 22.2 (–) |
Pi*PlowellZ (n = 1) | 15.8 (–) | 4.5 (–) | 35.3 (–) |
Pi*SZ (n = 13) | 14.2 (4.2) | 2.39 (0.6) | 58.8 (8.3) |
Pi*MZ (n = 13) | 9.78 (6.3) | 0.98 (0.5) | 97 (16.5) |
Pi*SMmalton (n = 1) | 6.9 (–) | 1.45 (–) | 47.9 (–) |
Pi*MMmattawa (n = 1) | 5.5 (–) | 0.8 (–) | 66.9 (–) |
Pi*MMvall d’hebron (n = 1) | 4.1 (–) | 0.3 (–) | 126 (–) |
Pi*MMmalton (n = 2) | 2.3 (3.2) | 0.2 (0.3) | 80.7 (18.5) |
Pi*SS (n = 3) | 0 | 0 | 84.1 (10.5) |
Pi*SI (n = 1) | 0 | 0 | 85.0 (–) |
Controls (n = 47) | |||
Pi*MM (n = 35) | 1.04 (1.73) | 0.06 (0.1) | 172.7 (34.3) |
Pi*MS (n = 12) | 0.9 (1.7) | 0.06 (0.1) | 142.7 (20.1) |